Technologies

We are a Poland-based CDMO and manufacturer of active pharmaceutical ingredients (APIs) that is proceeding with a $35 million facility expansion of its main API plant in Starogard Gdanski to include HPAPI and cryogenic technologies and investments in a pilot plant and R&D capabilities. We expect to extend our operations starting from Q1 2024, with full completion scheduled for Q3 2024.

2021
2022
2023
2024

Cryogenic Reactions Pilot Plant

Cryogenic Reactions Commercial Scale

Pilot scale

  • Reactor capacity range:
    0.1 to 0.5 m3
  • Operational temperature:
    down to -80oC

Commercial scale

  • Reactor capacity range:
    2.5 to 6.3 m3
  • Total reactors volume:
    23.5 m3
  • Operational temperature:
    down to -80oC